Associations - MDM2 amplification

MDM2 amplification MDM2 amplification	Liposarcoma Liposarcoma	MDM2 amplification MDM2 amplification	Liposarcoma Liposarcoma	APG-115 Sensitive: C2 – Inclusion Criteria	APG-115 Sensitive: C2 – Inclusion Criteria
MDM2 amplification MDM2 amplification	Solid Tumor Solid Tumor	MDM2 amplification MDM2 amplification	Solid Tumor Solid Tumor	RAIN-32 Sensitive: C2 – Inclusion Criteria	RAIN-32 Sensitive: C2 – Inclusion Criteria
MDM2 amplification MDM2 amplification	Liposarcoma Liposarcoma	MDM2 amplification MDM2 amplification	Liposarcoma Liposarcoma	RAIN-32 Sensitive: C2 – Inclusion Criteria	RAIN-32 Sensitive: C2 – Inclusion Criteria
MDM2 amplification MDM2 amplification	Liposarcoma Liposarcoma	MDM2 amplification MDM2 amplification	Liposarcoma Liposarcoma	BI 907828 Sensitive: C2 – Inclusion Criteria	BI 907828 Sensitive: C2 – Inclusion Criteria
MDM2 amplification MDM2 amplification	Mucosal Melanoma Mucosal Melanoma	MDM2 amplification MDM2 amplification	Mucosal Melanoma Mucosal Melanoma	ipilimumab Resistant: C3 – Early Trials	ipilimumab Resistant: C3 – Early Trials
MDM2 amplification MDM2 amplification	Mucosal Melanoma Mucosal Melanoma	MDM2 amplification MDM2 amplification	Mucosal Melanoma Mucosal Melanoma	nivolumab + ipilimumab Resistant: C3 – Early Trials	nivolumab + ipilimumab Resistant: C3 – Early Trials
MDM2 amplification MDM2 amplification	Mucosal Melanoma Mucosal Melanoma	MDM2 amplification MDM2 amplification	Mucosal Melanoma Mucosal Melanoma	nivolumab Resistant: C3 – Early Trials	nivolumab Resistant: C3 – Early Trials
MDM2 amplification MDM2 amplification	Mucosal Melanoma Mucosal Melanoma	MDM2 amplification MDM2 amplification	Mucosal Melanoma Mucosal Melanoma	pembrolizumab Resistant: C3 – Early Trials	pembrolizumab Resistant: C3 – Early Trials
MDM2 amplification MDM2 amplification	Gastric Adenocarcinoma Gastric Adenocarcinoma	MDM2 amplification MDM2 amplification	Gastric Adenocarcinoma Gastric Adenocarcinoma	Immunotherapy Resistant: C3 – Early Trials	Immunotherapy Resistant: C3 – Early Trials
MDM2 amplification MDM2 amplification	Sarcoma Sarcoma	MDM2 amplification MDM2 amplification	Sarcoma Sarcoma	RAIN-32 Sensitive: C3 – Early Trials	RAIN-32 Sensitive: C3 – Early Trials
MDM2 amplification MDM2 amplification	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	MDM2 amplification MDM2 amplification	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	R-CHOP Resistant: C3 – Early Trials	R-CHOP Resistant: C3 – Early Trials
MDM2 amplification MDM2 amplification	Solid Tumor Solid Tumor	MDM2 amplification MDM2 amplification	Solid Tumor Solid Tumor	BI 907828 + BI 754091 Sensitive: C3 – Early Trials	BI 907828 + BI 754091 Sensitive: C3 – Early Trials
MDM2 amplification MDM2 amplification	Triple Negative Breast Cancer Triple Negative Breast Cancer	MDM2 amplification MDM2 amplification	Triple Negative Breast Cancer Triple Negative Breast Cancer	pembrolizumab Resistant: C4 – Case Studies	pembrolizumab Resistant: C4 – Case Studies